Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation☆

Akita, Hidetaka; Kogure, Kentaro; Moriguchi, Rumiko; Nakamura, Yoshio; Higashi, T.; Nakamura, Takashi; Serada, Satoshi; Fujimoto, Minoru; Naka, Tetsuji; Futaki, Shiroh; Harashima, Hideyoshi

doi:10.1016/j.jconrel.2010.01.012

Cited by 134 publications

(114 citation statements)

References 35 publications

Supporting

Mentioning

110

Contrasting

Order By: Relevance

“…We also demonstrated gene silencing in DCs using multifunctional envelope-type nano device (MEND), a number of our original non-viral vector series [15,16]. The MEND is a lipid-based nanoparticle and is designed for controlling intracellular trafficking in addition to tissue distribution by virtue of being modified with several functional molecules and varying lipid components [17,18].…”

Section: Introductionmentioning

confidence: 99%

“…The MEND is a lipid-based nanoparticle and is designed for controlling intracellular trafficking in addition to tissue distribution by virtue of being modified with several functional molecules and varying lipid components [17,18]. The siRNA-loaded MEND, namely R8/GALA-MENDSUV, was constructed by mixing an siRNA/stearylated octaarginine (siRNA/STR-R8) complex with small unilamellar vesicles (SUVs), and the lipid surfaces of preparation was modified with STR-R8 and the GALA peptide [15,16]. The R8 peptide, a type of cell-penetrating peptide, increases the cell affinity of MEND and GALA peptide has a pH-sensitive fusogenic activity for enhancing endosomal escape [19,20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

Warashina

Nakamura

Sato

et al. 2016

Journal of Controlled Release

Self Cite

102

View full text Add to dashboard Cite

Applying small interfering RNA (siRNA) to dendritic cell (DC) based therapy excess of 90%, with a median effective dose (ED50) of 1.5 nM, whereas the maximum gene silencing efficiency of Lipofectamine RNAi MAX was less than 60% and the EC50 was 25 nM. Furthermore, a suppressor of cytokine signaling 1, an immune suppressive molecule in DCs, silenced in the mouse DC by the YSK12-MEND showed a drastic enhancement in cytokine production, resulting in the significant suppression of tumor growth when it was applied to DC-based therapy against a mouse lymphoma. These results clearly indicate that YSK12-MEND overcomes the obstacle associated with non-viral vectors and can be considered to be a promising non-viral vector for siRNA 2 delivery to DCs, thus accelerating DC-based therapies with siRNA.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

Warashina

Nakamura

Sato

et al. 2016

Journal of Controlled Release

Self Cite

102

View full text Add to dashboard Cite

show abstract

“…R8 modification facilitates cellular uptake of nanoparticles via macropinocytosis to avoid lysosomal degradation. The siRNA-loaded R8-modified nanoparticles efficiently reduced the endogenous SOCS1 gene expression and showed enhanced in vivo vaccine potential with suppressed tumor growth after immunization compared to the control BMDCs [34] .…”

Section: Dendritic Cellsmentioning

confidence: 98%

Role of targeting nanoparticles for cancer immunotherapy and imaging

Wen¹,

Umeano

2017

Trends Immunother

View full text Add to dashboard Cite

Cancer immunotherapy involves the delivery of immunogenic compounds and/or the priming, or induction, of the body's natural immune system to target cancer. The use of cancer immunotherapy has led to various means of cancer prevention and treatment that have produced prolonged life expectancy and stabilized disease. Nanoparticles are promising vehicles or adjuvants for effective delivery of therapeutics, antigens, stimulatory effectors, or antibodies for therapeutic invention. Targeting nanoparticles are especially useful due to their capability of accumulating in specific sites of interest like tumors and, thereby, decreasing risks of damage to normal tissue. Targeting can be achieved by incorporation of cell-surface related binding molecules or antibodies. This review explores the role of targeting nanoparticles as delivery or adjuvant systems to modulate immune response, and as imaging tracking systems for cancer immunotherapy. Keywords: nanoparticles; cancer immunotherapy; imaging; targeting ARTICLE INFO

show abstract

“…In this study it was demonstrated siRNA loaded in R8/GALA-MEND SUV efficiently suppresses endogenous gene expression and consequently enhances the potency of dendritic cell-based cancer vaccine. 62 …”

Section: Cytosolic Antigen Delivery and Endosomal Escapementioning

confidence: 99%

Multifunctional nanoparticles for cancer immunotherapy

Saleh

Shojaosadati

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

During the last decades significant progress has been made in the field of cancer immunotherapy. However, cancer vaccines have not been successful in clinical trials due to poor immunogenicity of antigen, limitations of safety associated with traditional systemic delivery as well as the complex regulation of the immune system in tumor microenvironment. In recent years, nanotechnology-based delivery systems have attracted great interest in the field of immunotherapy since they provide new opportunities to fight the cancer. In particular, for delivery of cancer vaccines, multifunctional nanoparticles present many advantages such as targeted delivery to immune cells, co-delivery of therapeutic agents, reduced adverse outcomes, blocked immune checkpoint molecules, and amplify immune activation via the use of stimuli-responsive or immunostimulatory materials. In this review article, we highlight recent progress and future promise of multifunctional nanoparticles that have been applied to enhance the efficiency of cancer vaccines.

show abstract

Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation☆

Cited by 134 publications

References 35 publications

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

Role of targeting nanoparticles for cancer immunotherapy and imaging

Multifunctional nanoparticles for cancer immunotherapy

Contact Info

Product

Resources

About